Daiichi Sankyo Co., Ltd. – Sponsored ADR (OTCMKTS:DSNKY) Short Interest Update

Daiichi Sankyo Co., Ltd. – Sponsored ADR (OTCMKTS:DSNKY) was the recipient of a significant increase in short interest in the month of March. As of March 13th, there was short interest totaling 419,845 shares, an increase of 240.6% from the February 26th total of 123,268 shares. Based on an average daily volume of 668,569 shares, the days-to-cover ratio is currently 0.6 days. Currently, 0.0% of the shares of the company are sold short. Currently, 0.0% of the shares of the company are sold short. Based on an average daily volume of 668,569 shares, the days-to-cover ratio is currently 0.6 days.

Daiichi Sankyo Stock Performance

Shares of OTCMKTS:DSNKY traded down $0.42 on Wednesday, reaching $18.66. 28,219 shares of the company’s stock were exchanged, compared to its average volume of 525,205. The business’s 50-day moving average is $19.05 and its two-hundred day moving average is $21.96. The company has a quick ratio of 1.85, a current ratio of 2.69 and a debt-to-equity ratio of 0.18. Daiichi Sankyo has a fifty-two week low of $17.44 and a fifty-two week high of $28.21. The firm has a market capitalization of $35.35 billion, a price-to-earnings ratio of 17.12, a PEG ratio of 1.15 and a beta of -0.35.

Daiichi Sankyo (OTCMKTS:DSNKY) last announced its quarterly earnings data on Thursday, January 29th. The company reported $0.30 earnings per share for the quarter, beating analysts’ consensus estimates of $0.25 by $0.05. The business had revenue of $3.65 billion during the quarter, compared to the consensus estimate of $3.88 billion. Daiichi Sankyo had a net margin of 14.83% and a return on equity of 18.64%. As a group, equities research analysts forecast that Daiichi Sankyo will post 0.73 EPS for the current year.

About Daiichi Sankyo

Daiichi Sankyo Co, Ltd. is a global, research-driven pharmaceutical company headquartered in Tokyo, Japan. The company was formed through the merger of Daiichi Pharmaceutical and Sankyo in 2005 and focuses on the discovery, development, manufacturing and commercialization of prescription medicines. Its therapeutic priorities include oncology and cardiovascular disease, and it pursues a mix of small molecules, biologics and antibody‑drug conjugates in its development programs.

Daiichi Sankyo is known for building a development portfolio through both internal research and collaborative partnerships.